Favipiravir NEW
| Price | $41 | $57 | $82 |
| Package | 5mg | 10mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-11 |
Product Details
| Product Name: Favipiravir | CAS No.: 259793-96-9 |
| Purity: 99.52% | Supply Ability: 10g |
| Release date: 2025/06/11 |
Product Introduction
Bioactivity
| Name | Favipiravir |
| Description | Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections. |
| Cell Research | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
| In vitro | METHODS: RAW 264.7 cells were infected with MNV at an MOI of 0,001 using a T-705 dilution series (3.13-200 lg/mL). The MTS CPE reduction method was used to determine the antiviral activity of T-705 in the MNV/RAW 264.7 cell line. After 3 days of incubation, complete CPE was observed in the infected untreated cells. The cell culture supernatant was collected and analyzed by quantitative RT- PCR (qRT-PCR) quantitatively detects viral RNA load. RESULTS T-705 inhibited MNV-induced CPE (EC50: 39 ± 4 lg/mL [250 ± 11 lM]) and MNV RNA synthesis in cell culture (EC50: 19 ± 6 lg/mL [124 ± 42 lM]). [2] |
| In vivo | METHODS: When Favipiravir (T-705) is used at a dose of 1-100mg/kg and infected with a lethal dose of influenza virus A/Victoria/3/75 (H3N2), A/Osaka/5/70 (H3N2) or A/ Duck/MN/1525/81 (H5N1) was administered orally 2 or 4 times a day to mice for 5 days, and the survival rate of the mice was observed. RESULTS Favipiravir (T-705) showed improved survival compared with placebo at doses of 30 mg/kg/day or higher, the drug was also administered at doses of 33 mg/kg/day or higher Provides significant protection against A/Duck/MN/1525/81 (H5N1) virus. [1] METHODS: Favipiravir was administered at 120 mg/kg/day or 200 mg/kg/day on days 1-5 after lethal SFTSV infection in type I interferon receptor knockout (IFNAR ?/?) mice. (T-705) and continued for 5 days to observe the growth status of the mice. RESULTS All favipiravir-treated mice at doses of 120 mg/kg/day or 200 mg/kg/day, respectively, survived lethal SFTSV infection when treatment was initiated within 3 and 4 days of infection. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 12 mg/mL (76.38 mM), Sonication is recommended. H2O : 5 mg/mL (31.83 mM), Sonication is recommended. DMSO : 45 mg/mL (286.44 mM), Sonication is recommended. |
| Keywords | T705 | T 705 | SARS-CoV | SARSCoV | SARS coronavirus | RNASynthesis | RNA-dependent RNA polymerase | RNA Synthesis | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | Favipiravir | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis |
| Inhibitors Related | 5-Fluorouracil | Acetylcysteine | Procaine | Hydroxychloroquine | Guanidine hydrochloride | Methotrexate disodium | Nitazoxanide | Curcumin | Thymidine | Naringenin | Salcomine | Crystal Violet |
| Related Compound Libraries | Bioactive Compound Library | Pediatric Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $150.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-24 | |
| $25.00/1ASSAYS |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-20 | |
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-10-11 | |
| $0.00/1kg |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-10 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-13 | |
| $10.00/1kg |
Wuhan Xinhao Biotechnology Co., Ltd
|
2024-03-12 | ||
| $10.00/1kg |
Nantong Guangyuan Chemicl Co,Ltd
|
2023-11-02 | ||
| $40.00/1kg |
VIP6Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-11 | |
| $30.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-09-07 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY